A clinical prediction model based on 68Ga-PSMA-11 PET/CT and mpMRI parameters to determine the diagnostic accuracy of targeted biopsy alone in prostate cancer population
A clinical prediction model based on 68Ga-PSMA-11 PET/CT and mpMRI parameters to determine the diagnostic accuracy of targeted biopsy alone in prostate cancer population
Objective To develop a clinical prediction model based on 68 Ga-prostate-specific membrane antigen-11(68Ga-PSMA-11),positron emission tomography/computed tomography(PET/CT)and multiparametric magnetic resonance imaging(mpMRI)parameters to stratify prostate cancer patients undergoing targeted biopsy,so as to avoid unnecessary systematic biopsy.Methods A total of 96 clinically significant prostate cancer(csPCa)patients who underwent 68Ga-PSMA-11 PET/CT and mpMRI prior to prostate targeted biopsy with systematic biopsy during Jan.2020 and Feb.2023 in Nanjing Drum Tower Hospital were retrospectively analyzed.By univariate and multivariate logistic regression analyses,maximum standard uptake value(SUVmax)in 68 Ga-PSMA-11 PET/CT and minimum apparent diffusion coefficien(ADCmin)in mpMRI,as well as clinical parameters were evaluated to identify the independent predictors correlative with the effective diagnosis of targeted biopsy,and a clinical prediction model was constructed.Results Multivariate logistic regression analysis showed that SUVmax(OR=0.878,95％CI:0.804-0.959,P=0.004)and ADCmin(OR=1.005,95％CI:1.001-1.010,P=0.027)were independent predictors of the effective diagnosis of targeted biopsy alone.The sensitivity,specificity,accuracy and area under the receiver operator characteristic curve(AUC)of the model were 0.80,0.80,0.83 and 0.84,respectively.Conclusion The clinical prediction model based on 68Ga-PSMA-11 PET/CT and mpMRI parameters is helpful to improve the effective diagnosis of targeted biopsy alone,and has practical value to stratify patients with csPCa so as to safely avoid systematic biopsy and effectively balance the benefits and risks.
万方数据